FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912293021> ?p ?o ?g. }

• W2912293021 endingPage "1024" @default.
• W2912293021 startingPage "1014" @default.
• W2912293021 abstract "ABSTRACT Mineral and bone disorders including osteoporosis are common in dialysis patients and contribute to increased morbimortality. However, whether denosumab and alendronate are effective and safe treatments in hemodialysis patients is not known. Thus, we conducted a prospective, three‐center study of 48 hemodialysis patients who were diagnosed as having osteoporosis and had not received anti‐osteoporotic agents previously. Participants were randomized to either denosumab or intravenous alendronate, and all subjects received elemental calcium and calcitriol during the initial 2 weeks. The primary endpoint was the percent change in lumbar spine bone mineral density (LSBMD) at 12 months of treatment. The secondary endpoints included the following: change in BMD at other sites; change of serum bone turnover markers (BTM), coronary artery calcium score (CACS), ankle‐brachial pressure index (ABI), brachial‐ankle pulse wave velocity (baPWV), flow mediated dilation (FMD), and intima‐media thickness at the carotid artery (CA‐IMT); change from day 0 to day 14 in serum levels of Ca and P; time course of serum calcium (Ca), phosphorus (P), and intact parathyroid hormone (i‐PTH); new fractures; and adverse events. Initial supplementation with elemental calcium and calcitriol markedly ameliorated the decrease of serum corrected calcium (cCa) levels induced by denosumab during the first 2 weeks, whereas serum cCa levels in the alendronate group were increased. Denosumab and alendronate markedly decreased serum levels of BTM and increased LSBMD at 12 months compared with baseline. However, no significant differences were found in the changes in LSBMD between the two groups. The serum cCa, P, and i‐PTH levels in the two groups were maintained within the appropriate range. In contrast to the anti‐osteoporotic effects, no significant differences after 12 months of treatment were found in the CACS, CA‐IMT, ABI, baPWV, and FMD compared with pretreatment in both groups. Denosumab and alendronate treatment improved LSBMD, reduced BTM, and appeared to be safe in hemodialysis patients with osteoporosis. © 2019 American Society for Bone and Mineral Research." @default.
• W2912293021 created "2019-02-21" @default.
• W2912293021 creator A5011652270 @default.
• W2912293021 creator A5018770573 @default.
• W2912293021 creator A5019432963 @default.
• W2912293021 creator A5023592217 @default.
• W2912293021 creator A5033387432 @default.
• W2912293021 creator A5049417272 @default.
• W2912293021 creator A5063916618 @default.
• W2912293021 creator A5064424624 @default.
• W2912293021 creator A5081972641 @default.
• W2912293021 creator A5089181291 @default.
• W2912293021 date "2019-03-04" @default.
• W2912293021 modified "2023-10-14" @default.
• W2912293021 title "Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial" @default.
• W2912293021 cites W1494926937 @default.
• W2912293021 cites W1827628162 @default.
• W2912293021 cites W1912199041 @default.
• W2912293021 cites W1965511198 @default.
• W2912293021 cites W1969338811 @default.
• W2912293021 cites W1980175801 @default.
• W2912293021 cites W1985310164 @default.
• W2912293021 cites W2001110947 @default.
• W2912293021 cites W2008613910 @default.
• W2912293021 cites W2024548298 @default.
• W2912293021 cites W2044178924 @default.
• W2912293021 cites W2049436429 @default.
• W2912293021 cites W2049696849 @default.
• W2912293021 cites W2055233141 @default.
• W2912293021 cites W2071070401 @default.
• W2912293021 cites W2080074686 @default.
• W2912293021 cites W2083982449 @default.
• W2912293021 cites W2126750245 @default.
• W2912293021 cites W2147365718 @default.
• W2912293021 cites W2153009489 @default.
• W2912293021 cites W2153785016 @default.
• W2912293021 cites W2346267426 @default.
• W2912293021 cites W2472441389 @default.
• W2912293021 cites W2605743908 @default.
• W2912293021 cites W2614075773 @default.
• W2912293021 cites W2799301447 @default.
• W2912293021 cites W4232051506 @default.
• W2912293021 doi "https://doi.org/10.1002/jbmr.3676" @default.
• W2912293021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30690785" @default.
• W2912293021 hasPublicationYear "2019" @default.
• W2912293021 type Work @default.
• W2912293021 sameAs 2912293021 @default.
• W2912293021 citedByCount "57" @default.
• W2912293021 countsByYear W29122930212019 @default.
• W2912293021 countsByYear W29122930212020 @default.
• W2912293021 countsByYear W29122930212021 @default.
• W2912293021 countsByYear W29122930212022 @default.
• W2912293021 countsByYear W29122930212023 @default.
• W2912293021 crossrefType "journal-article" @default.
• W2912293021 hasAuthorship W2912293021A5011652270 @default.
• W2912293021 hasAuthorship W2912293021A5018770573 @default.
• W2912293021 hasAuthorship W2912293021A5019432963 @default.
• W2912293021 hasAuthorship W2912293021A5023592217 @default.
• W2912293021 hasAuthorship W2912293021A5033387432 @default.
• W2912293021 hasAuthorship W2912293021A5049417272 @default.
• W2912293021 hasAuthorship W2912293021A5063916618 @default.
• W2912293021 hasAuthorship W2912293021A5064424624 @default.
• W2912293021 hasAuthorship W2912293021A5081972641 @default.
• W2912293021 hasAuthorship W2912293021A5089181291 @default.
• W2912293021 hasBestOaLocation W29122930211 @default.
• W2912293021 hasConcept C126322002 @default.
• W2912293021 hasConcept C126894567 @default.
• W2912293021 hasConcept C134018914 @default.
• W2912293021 hasConcept C168563851 @default.
• W2912293021 hasConcept C170033053 @default.
• W2912293021 hasConcept C203092338 @default.
• W2912293021 hasConcept C2776079296 @default.
• W2912293021 hasConcept C2776286101 @default.
• W2912293021 hasConcept C2776541429 @default.
• W2912293021 hasConcept C2776886416 @default.
• W2912293021 hasConcept C2778063415 @default.
• W2912293021 hasConcept C2781208988 @default.
• W2912293021 hasConcept C519063684 @default.
• W2912293021 hasConcept C71924100 @default.
• W2912293021 hasConcept C90924648 @default.
• W2912293021 hasConceptScore W2912293021C126322002 @default.
• W2912293021 hasConceptScore W2912293021C126894567 @default.
• W2912293021 hasConceptScore W2912293021C134018914 @default.
• W2912293021 hasConceptScore W2912293021C168563851 @default.
• W2912293021 hasConceptScore W2912293021C170033053 @default.
• W2912293021 hasConceptScore W2912293021C203092338 @default.
• W2912293021 hasConceptScore W2912293021C2776079296 @default.
• W2912293021 hasConceptScore W2912293021C2776286101 @default.
• W2912293021 hasConceptScore W2912293021C2776541429 @default.
• W2912293021 hasConceptScore W2912293021C2776886416 @default.
• W2912293021 hasConceptScore W2912293021C2778063415 @default.
• W2912293021 hasConceptScore W2912293021C2781208988 @default.
• W2912293021 hasConceptScore W2912293021C519063684 @default.
• W2912293021 hasConceptScore W2912293021C71924100 @default.
• W2912293021 hasConceptScore W2912293021C90924648 @default.
• W2912293021 hasFunder F4320324576 @default.
• W2912293021 hasIssue "6" @default.
• W2912293021 hasLocation W29122930211 @default.

• next